Glaxosmithkline Biologicals Sa

Novartis Ag

Novartis Vaccines and Diagnostics Srl

J. Craig Venter Institute

J. Craig Venture Institute, Inc.

Laura Serino

Maria Rita Fontana

Danilo Gomes Moriel

Mariagrazia Pizza

Francesco Berlanda Scorza

Vega Masignani

Herve Tettelin

Nathalie Norais

Paolo Costantino

Francesco Berti

Maria Rosaria Romano

Francesca Micoli

Anna Kabanova

Marta Tontini

Homologs of theproteins orf353, bacterial lg-like domain (group 1) protein (orf405), flu antigen 43 (orf1 364), NodT-family outer-membrane-factor-lipoprotein efflux transporter (orf1 767), gspK (orf3515), gspJ (orf3516), toriB-dependent siderophore receptor (orO597), fibrial protein (orf3613), upec-948, upec-1232. A chain precursor of the type-1 fimbria! protein (upec-1875), yapH homolog (upec-2820), hemolysin A (recp-3768), and Sel 1 repeat-containing protein (upec-521 1) from several pathogenic strains ofhave been identified with regions within the proteins that are conserved across all. Fragments corresponding to the conserved regions, especially immunogenic fragments such a linear B-epitopes, are provided. In addition, variants of the bacterial lg-like domain (group 1) protein (orf405), yapH homolog (upec2820) and two different fragments of hemolysin A (recp3768) are provided herein that have increased solubility as compared to the native protein where the variants still raise a substantially similar immune response in a subject as the corresponding native protein.

Conservedbacterial IG-like domain (group 1) protein (ORF405) immunogens

The invention provides an immunogenic composition comprising a combination of (i) bacterial Ig-like domain protein fragment (orf405B) having the amino acid sequence set forth in SEQ ID NO:2 or a protein having at least 80% similarity thereto, and (ii) putative Lipoprotein (orf3526) having the amino acid sequence set forth in SEQ ID NO:8 or a protein having at least 80% similarity thereto.

[object Object]

Detoxified variants of the pathogenic'AcfD precursor' (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (orB526) protein. The detoxified variants may be further modified to have increased solubility as compared to the native AcfD (orf3526) protein.

Disclosed herein are various open reading frames from a strain ofresponsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.

proteins have been identified that are useful as carrier proteins to improve a response to a polysaccharide immunogen conjugated to such protein. In particular, AcfD precursor protein (orf3526 polypeptide), Flu antigen 43 protein (orf1364 polypeptide), and Sel1 repeat-containing protein (upec-5211 polypeptide) have been shown to be effective. Additionally, theseproteins can enhance the immune response to glucans, particularly fungal glucans.

Polysaccharide immunogens conjugated to E. coli carrier proteins

Variants of the pathogenic'AcfD precursor' have been identified with increased solubility as compared to the native AcfD protein that raise a substantially similar immune response in a subject as the native AcfD protein.

Disclosed herein are various open reading frames from a strain ofresponsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.

Disclosed herein are various genes that can be included in immunogenic compositions specific for pathogenicstrains. The genes are from uropathogenic strains but are absent from non-pathogenic strains, and their encoded proteins have cellular locations which render them accessible to the immune system.

Growing community of inventors

Monticiano, Italy

Laura Serino